

Edgar Filing: ENZO BIOCHEM INC - Form SC 13G/A

ENZO BIOCHEM INC  
Form SC 13G/A  
January 05, 2006  
\

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(AMENDMENT NO. 5) \*

Enzo Biochem, Inc.

-----  
(Name of Issuer)

Common Stock

-----  
(Title of Class of Securities)

294100-10-2

-----  
(CUSIP Number)

December 31, 2005

-----  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

/X/ Rule 13d-1(b)  
/ / Rule 13d-1(c)  
/ / Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1  
of 9 Pages

SCHEDULE 13G

CUSIP NO. 294100-10-2

Page 2 of 9 Pages

Edgar Filing: ENZO BIOCHEM INC - Form SC 13G/A

(1) NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Citigroup Global Markets Inc.

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) / /  
(b) / /

(3) SEC USE ONLY

(4) CITIZENSHIP OR PLACE OF ORGANIZATION New York

NUMBER OF SHARES	(5) SOLE VOTING POWER	0
---------------------	-----------------------	---

BENEFICIALLY OWNED BY	(6) SHARED VOTING POWER	261,928*
--------------------------	-------------------------	----------

EACH REPORTING	(7) SOLE DISPOSITIVE POWER	0
-------------------	----------------------------	---

PERSON WITH:	(8) SHARED DISPOSITIVE POWER	261,928*
-----------------	------------------------------	----------

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 261,928\*

(10) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) / /

(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.8%\*

(12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) BD

\* Prior to the sale of Smith Barney Fund Management LLC and the Asset Management division of Citigroup Global Markets Inc. to Legg Mason, Inc. effective as of December 1, 2005 (the "Sale"), Citigroup Global Markets

Edgar Filing: ENZO BIOCHEM INC - Form SC 13G/A

Inc., Citigroup Financial Products Inc., Citigroup Global Markets Holdings Inc. and Citigroup Inc. (collectively, the "Reporting Persons") beneficially owned more than 5% of the Issuer's securities. Upon completion of the Sale, the Reporting Persons no longer beneficially owned more than 5% of the Issuer's securities.

SCHEDULE 13G

CUSIP NO. 294100-10-2

Page 3 of 9 Pages

-----  
 (1) NAMES OF REPORTING PERSONS  
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
  
 Citigroup Financial Products Inc.  
 -----

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  
  
(a) / /  
(b) / /  
 -----

(3) SEC USE ONLY  
 -----

(4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware  
 -----

NUMBER OF	(5) SOLE VOTING POWER	0
SHARES		
BENEFICIALLY	(6) SHARED VOTING POWER	261,928*
OWNED BY		
EACH	(7) SOLE DISPOSITIVE POWER	0
REPORTING		
PERSON	(8) SHARED DISPOSITIVE POWER	261,928*
WITH:		

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 261,928\*  
 -----

(10) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) / /  
 -----

(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.8%\*  
 -----

Edgar Filing: ENZO BIOCHEM INC - Form SC 13G/A

-----  
(12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO

-----  
\* Prior to the Sale, the Reporting Persons beneficially owned more than 5% of the Issuer's securities. Upon completion of the Sale, the Reporting Persons no longer beneficially owned more than 5% of the Issuer's securities.

SCHEDULE 13G

CUSIP NO. 294100-10-2

Page 4 of 9 Pages

-----  
(1) NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Citigroup Global Markets Holdings Inc.

-----  
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) / /

(b) / /

-----  
(3) SEC USE ONLY

-----  
(4) CITIZENSHIP OR PLACE OF ORGANIZATION New York

-----  
NUMBER OF (5) SOLE VOTING POWER 0  
SHARES

-----  
BENEFICIALLY (6) SHARED VOTING POWER 263,584\*

-----  
OWNED BY  
EACH (7) SOLE DISPOSITIVE POWER 0

-----  
REPORTING  
PERSON (8) SHARED DISPOSITIVE POWER 263,584\*

WITH:

-----  
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 263,584\*

-----  
(10) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) / /

Edgar Filing: ENZO BIOCHEM INC - Form SC 13G/A

-----  
 (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.8%\*

-----  
 (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

-----  
 \* Prior to the Sale, the Reporting Persons beneficially owned more than 5% of the Issuer's securities. Upon completion of the Sale, the Reporting Persons no longer beneficially owned more than 5% of the Issuer's securities.

SCHEDULE 13G

CUSIP NO. 294100-10-2

Page 5 of 9 Pages

-----  
 (1) NAMES OF REPORTING PERSONS  
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Citigroup Inc.

-----  
 (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) / /  
 (b) / /

-----  
 (3) SEC USE ONLY

-----  
 (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

-----  
 NUMBER OF (5) SOLE VOTING POWER 0

SHARES

-----  
 BENEFICIALLY (6) SHARED VOTING POWER 279,468\*  
 \*\*

OWNED BY

-----  
 EACH (7) SOLE DISPOSITIVE POWER 0

REPORTING

-----  
 PERSON (8) SHARED DISPOSITIVE POWER 279,468\*  
 \*\*

WITH:

-----  
 (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 279,468\*  
 \*\*

Edgar Filing: ENZO BIOCHEM INC - Form SC 13G/A

-----  
(10) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) / /

-----  
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.9%\*  
\*\*

-----  
(12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

-----  
\* Prior to the Sale, the Reporting Persons beneficially owned more than 5% of the Issuer's securities. Upon completion of the Sale, the Reporting Persons no longer beneficially owned more than 5% of the Issuer's securities.  
\*\* Includes shares held by the other reporting persons.

Item 1(a). Name of Issuer:

Enzo Biochem, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

60 Executive Blvd.  
Farmingdale, New York 11735

Item 2(a). Name of Person Filing:

Citigroup Global Markets Inc. ("CGM")  
Citigroup Financial Products Inc. ("CFP")  
Citigroup Global Markets Holdings Inc. ("CGM Holdings")  
Citigroup Inc. ("Citigroup")

Item 2(b). Address of Principal Office or, if none, Residence:

The address of the principal office of each of CGM, CFP and CGM Holdings is:

388 Greenwich Street  
New York, NY 10013

The address of the principal office of Citigroup is:  
399 Park Avenue  
New York, NY 10043

Item 2(c). Citizenship or Place of Organization:

CGM and CGM Holdings are New York corporations.  
CFP and Citigroup are Delaware corporations.

Item 2(d). Title of Class of Securities:

Common Stock

Edgar Filing: ENZO BIOCHEM INC - Form SC 13G/A

Item 2(e). CUSIP Number:  
294100-10-2

Page 6  
of 9 Pages

Item 3. If This Statement is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

- (a)  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
- (f)  Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
- (g)  Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
- (h)  Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).

Item 4. Ownership. (as of December 31, 2005)

- (a) Amount beneficially owned: See item 9 of cover pages
- (b) Percent of Class: See item 11 of cover pages
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote:
  - (ii) Shared power to vote or to direct the vote:
  - (iii) Sole power to dispose or to direct the disposition of:
  - (iv) Shared power to dispose or to direct the disposition of:

See Items 5-8 of cover pages

Edgar Filing: ENZO BIOCHEM INC - Form SC 13G/A

Page 7  
of 9 Pages

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security being Reported on by the Parent Holding Company.

CFP is the sole stockholder of CGM. CGM Holdings is the sole stockholder of CFP. Citigroup is the sole stockholder of CGM Holdings.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Page 8  
of 9 Pages

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 5, 2006

CITIGROUP GLOBAL MARKETS INC.

By: /s/ Ali L. Karshan



Edgar Filing: ENZO BIOCHEM INC - Form SC 13G/A

-----  
Name: Ali L. Karshan  
Title: Assistant Secretary

CITIGROUP FINANCIAL PRODUCTS INC.

By: /s/ Ali L. Karshan

-----  
Name: Ali L. Karshan  
Title: Assistant Secretary

CITIGROUP GLOBAL MARKETS HOLDINGS INC.

By: /s/ Ali L. Karshan

-----  
Name: Ali L. Karshan  
Title: Assistant Secretary

CITIGROUP INC.

By: /s/ Ali L. Karshan

-----  
Name: Ali L. Karshan  
Title: Assistant Secretary

Page 9  
of 9 Pages

EXHIBIT INDEX TO SCHEDULE 13G  
-----

EXHIBIT 1  
-----

Agreement among CGM, CFP, CGM Holdings and Citigroup as to joint filing of  
Schedule 13G.